Abstract
Objective: To estimate the probability of clinical or multiple pregnancy during ovulation induction (OI)/ovarian stimulation (OS). Design: Secondary analysis of two multicenter randomized clinical trials (combined). Setting: Multicenter. Patients: A total of 750 women with polycystic ovary syndrome and 900 women with unexplained infertility. Interventions: Ovulation induction/OS with either timed intercourse (polycystic ovary syndrome) or intrauterine insemination. Main Outcome Measures: Clinical and multiple pregnancy rates/cycle, cumulative pregnancy rates. Age, body mass index, parity, diagnosis, medication, markers of ovarian reserve, and ovarian response were considered in multivariable regression models for clinical, multiple, and cumulative pregnancy rates. Receiver operating characteristic curves were created for clinical and multiple pregnancy rates. Results: Younger patient and partner age, treatment type, lower body mass index, and medication dose were all associated with clinical pregnancy. Variables associated with multiple pregnancy included the abovementioned variables (except age), in addition to diagnosis, parity, higher antral follicle count, antimüllerian hormone levels, and ovarian response. Gonadotropin use was associated with multiple pregnancy, with progressively increasing odds ratios (cycles 1–4). Receiver operating characteristic curves indicated the model's predictive power to be fair for clinical pregnancy (areas under the curve [95% confidence interval {CI}]: 0.78 [0.75–0.81] for cycle 1 and 0.70 [0.64–0.75] for cycle 4) and good-to-excellent for multiple pregnancy (areas under the curve [95% CI]: 0.78 [0.72–0.84] for cycle 1 and 0.86 [0.78–0.93] for cycle 4). Partner age, lower medication dose, parity, antimüllerian hormone levels, and diagnosis were associated with cumulative pregnancy rates. Conclusions: Using the majority of the factors known to predict the outcome of OI/OS cycles, we constructed an easy-to-use formula that may predict individualized chances of clinical and multiple pregnancy for commonly used fertility treatments (https://pregnancyprediction.medicine.yale.edu/CalDirect.html). Clinical Trial Registration Numbers: Assessing Multiple Intrauterine Gestations after Ovulation Stimulation NCT 1044862; PPCOSII NCT00719186.
Original language | English (US) |
---|---|
Pages (from-to) | 408-418 |
Number of pages | 11 |
Journal | Fertility and sterility |
Volume | 117 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2022 |
Keywords
- Ovulation induction
- individualized prediction models
- ovarian stimulation
- probability of clinical pregnancy
- probability of multiple pregnancy
ASJC Scopus subject areas
- Reproductive Medicine
- Obstetrics and Gynecology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'A personalized medicine approach to ovulation induction/ovarian stimulation: development of a predictive model and online calculator from level-I evidence'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
A personalized medicine approach to ovulation induction/ovarian stimulation : development of a predictive model and online calculator from level-I evidence. / for the Eunice Kennedy Schriver National Institute of Child Health and Human Development Reproductive Medicine Network.
In: Fertility and sterility, Vol. 117, No. 2, 02.2022, p. 408-418.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - A personalized medicine approach to ovulation induction/ovarian stimulation
T2 - development of a predictive model and online calculator from level-I evidence
AU - for the Eunice Kennedy Schriver National Institute of Child Health and Human Development Reproductive Medicine Network
AU - Souter, Irene
AU - Sun, Fangbai
AU - Zhang, Heping
AU - Diamond, Michael P.
AU - Legro, Richard S.
AU - Wild, Robert A.
AU - Hansen, Karl R.
AU - Santoro, Nanette
N1 - Funding Information: Supported by grants from the National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R25HD075737 [to N.S.], U10 HD39005 [to M.P.D.], U10 HD38992 [to R.S.L.], U10 HD055925 [to H.Z.], and U10 HD077680 [to K.R.H.]). Funding Information: I.S. has nothing to disclose. F.S. has nothing to disclose. H.Z. reports grants form National Institutes of Health (NIH). M.P.D. reports grants from NIH/NICHD 5U10 HD039005 for the submitted work and is a member of the Board of Directors and stockholder for Advanced Reproductive Care. R.S.L. reports grants from NIH R01 HD091350-04, NIH/NCCIH R01AT009484-02, Guerbet USA, Data Coordinator Center for the RMN U10HD055925-10REV, Hass Avocado Board; Penn State Clinical and Translational Science Institute, NIH/NICHS R01 HD083323-04, NIH R01HD100630-01, National Center for Advancing Translational Sciences UL1 TR002014, NIH U10 HD038992-15 (Ext), NIH/NICHD U10 HD038992-10 (Ext), NIH/NHLBI R01 HL119245-05, and Patty Brisben Foundation for Women’s Sexual Health; consulting fees from Insudd (2020), Bayer (2019), Fractyl (2019), AbbVie (2019), and Ferring (2018); honorarium/payment for lectures from National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Shandong University, Jinan, China; Member, Steering Committee, Eastern Siberia PCOS Epidemiology & Phenotype study, Scientific Center of Family Health and Human Reproduction, Irkutsk, Russian Federation; Member, International Advisory Panel, Developing, disseminating and implementing a core outcome set for infertility, Funded by the Royal Society of New Zealand Catalyst Fund and the University of Auckland, New Zealand; Member, International Advisory Panel, International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS), funded by The Australian National Health and Medical Research Council (NHMRC) through the Centre for Research Excellence in Polycystic Ovary Syndrome, Monash University, Melbourne, Australia; Invited Speaker, 28th Brazilian Congress of Human Reproduction, Belo Horizonte, Brazil; Invited Speaker and Panel Member, 2019 IFFS World Congress, Shanghai, China; Invited Speaker, Penn State College of Medicine Emeritus Faculty Organization Spring Meeting, Penn State College of Medicine, Hershey, Pennsylvania; Invited Speaker, Annual Meeting of ACOG, Nashville, Tennessee; Invited Speaker, 30 Años Aniversario IDIMI (Instituto de Investigaciones Materno – Infantil, Universidad de Chile), Eje Gonadal, Genética y Ambiente, Desde la Infancia a la Adultez, Santiago, Chile; Invited Speaker, 35th Annual Meeting of the European Society of Human Reproduction and Embryology, Vienna, Austria; Webinar Speaker, The PCOS Society of India; Invited Speaker, PEACOCKS Biennial Meeting, Mas de Torrent, Costa Brava, Spain; Invited Speaker, 2019 Canadian Society of Endocrinology and Metabolism/Diabetes Canada Professional and Annual Meeting, Winnipeg, Manitoba; Invited Speaker, University of California at San Diego Ob/Gyn Grand Rounds. San Diego, California; Invited Speaker, Obesity Week, Las Vegas, Nevada; Visiting Professor and Invited Speaker, Seminars in Obstetrics, Gynecology and Reproductive Biology; and Grand Rounds Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, Kansas; Invited Webinar Speaker, Human Reproduction Update Chinese Edition Young Editor Meeting; Invited Webinar Speaker, Obesity and Women’s Health Webinar: NIH Obesity Research Task Force Seminar Series; and Advisor, A metabolomic approach to redefine diagnostic criteria and classification of polycystic ovary syndrome (principal investigator: Professor Chi Chui Wang, Chinese University of Hong Kong). Funded by the Research Fund, Food and Health Bureau, The Government of the Hong Kong Special Administrative Region (there are no in-person meetings); has been a member of PCOS Challenge (patient support group), Medical/Scientific Advisory Board; Endocrine Society: Member Executive Committee (2015–2018); Secretary-Treasurer (2016–2018); Member Investment Subcommittee (2018–present); and International Advisory Board and Guideline Committee, NHMRC-funded Centre for Research Excellence in PCOS, Melbourne, Australia (June 2016–May 2018); has been a Co-Editor in Chief, Seminars in Reproductive Medicine (2015–2019); Associate Editor, Human Reproduction Update (2017–2020); Associate Editor, Fertility and Sterility (2009–2020); Editorial Editor, Fertility and Sterility (2020–present); Associate Editor, Global Reproductive Health (2017–present); and member, Editorial Board, Endocrinology (2016–2019); is the owner of 1000 shares of Biodesix (BDSX); reports financial or nonfinancial interests as follows: NIH: ZHD1 DSR-K (LR) 1 Loan Repayment Program (Annually, 2008–present), U54 Contraceptive Center Grant, Special Emphasis Panel ZHD1 DSR – L50 (2017), Special Emphasis Panel/Scientific Review Group 05 CHHD-W 1 Population Sciences Subcommittee (2018), Special Emphasis Panel/Scientific Review Group 10 ZHD1 DSR-M (55): National Centers for Translational Research in Reproduction and Infertility (2020); and Kuwait Foundation for the Advancement of Science (KFAS) (2017) Appalachian Translational Research Network (ATRN) (2018), Karolinska Institute, Stockholm, Sweden (2020). R.A.W. has nothing to disclose. K.R.H. reports grants from the Reproductive Medicine Network (NIH U10HD077680); grants form NIH (NIH R03HD101893 and NIH R01HD100305) outside the submitted work; and consulting fees from AblaCare outside the submitted work. N.S. reports grants from NIH (NIH R25 HD075737). Funding Information: The authors acknowledge the following individuals for their help in the development of the calculator: Jiuzhou Wang, Ph.D. student (Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota), Yajie Duan, Ph.D. student (Department of Statistics, Rutgers, the State University of New Jersey, Piscataway, New Jersey), and Zhe Cai, M.P.S. student in Analytics (College of Professional Studies, Northeastern University, Boston, Massachusetts). DIALOG: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/posts/33035 I.S. has nothing to disclose. F.S. has nothing to disclose. H.Z. reports grants form National Institutes of Health (NIH). M.P.D. reports grants from NIH/NICHD 5U10 HD039005 for the submitted work and is a member of the Board of Directors and stockholder for Advanced Reproductive Care. R.S.L. reports grants from NIH R01 HD091350-04, NIH/NCCIH R01AT009484-02, Guerbet USA, Data Coordinator Center for the RMN U10HD055925-10REV, Hass Avocado Board; Penn State Clinical and Translational Science Institute, NIH/NICHS R01 HD083323-04, NIH R01HD100630-01, National Center for Advancing Translational Sciences UL1 TR002014, NIH U10 HD038992-15 (Ext), NIH/NICHD U10 HD038992-10 (Ext), NIH/NHLBI R01 HL119245-05, and Patty Brisben Foundation for Women's Sexual Health; consulting fees from Insudd (2020), Bayer (2019), Fractyl (2019), AbbVie (2019), and Ferring (2018); honorarium/payment for lectures from National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Shandong University, Jinan, China; Member, Steering Committee, Eastern Siberia PCOS Epidemiology & Phenotype study, Scientific Center of Family Health and Human Reproduction, Irkutsk, Russian Federation; Member, International Advisory Panel, Developing, disseminating and implementing a core outcome set for infertility, Funded by the Royal Society of New Zealand Catalyst Fund and the University of Auckland, New Zealand; Member, International Advisory Panel, International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS), funded by The Australian National Health and Medical Research Council (NHMRC) through the Centre for Research Excellence in Polycystic Ovary Syndrome, Monash University, Melbourne, Australia; Invited Speaker, 28th Brazilian Congress of Human Reproduction, Belo Horizonte, Brazil; Invited Speaker and Panel Member, 2019 IFFS World Congress, Shanghai, China; Invited Speaker, Penn State College of Medicine Emeritus Faculty Organization Spring Meeting, Penn State College of Medicine, Hershey, Pennsylvania; Invited Speaker, Annual Meeting of ACOG, Nashville, Tennessee; Invited Speaker, 30 A?os Aniversario IDIMI (Instituto de Investigaciones Materno ? Infantil, Universidad de Chile), Eje Gonadal, Gen?tica y Ambiente, Desde la Infancia a la Adultez, Santiago, Chile; Invited Speaker, 35th Annual Meeting of the European Society of Human Reproduction and Embryology, Vienna, Austria; Webinar Speaker, The PCOS Society of India; Invited Speaker, PEACOCKS Biennial Meeting, Mas de Torrent, Costa Brava, Spain; Invited Speaker, 2019 Canadian Society of Endocrinology and Metabolism/Diabetes Canada Professional and Annual Meeting, Winnipeg, Manitoba; Invited Speaker, University of California at San Diego Ob/Gyn Grand Rounds. San Diego, California; Invited Speaker, Obesity Week, Las Vegas, Nevada; Visiting Professor and Invited Speaker, Seminars in Obstetrics, Gynecology and Reproductive Biology; and Grand Rounds Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, Kansas; Invited Webinar Speaker, Human Reproduction Update Chinese Edition Young Editor Meeting; Invited Webinar Speaker, Obesity and Women's Health Webinar: NIH Obesity Research Task Force Seminar Series; and Advisor, A metabolomic approach to redefine diagnostic criteria and classification of polycystic ovary syndrome (principal investigator: Professor Chi Chui Wang, Chinese University of Hong Kong). Funded by the Research Fund, Food and Health Bureau, The Government of the Hong Kong Special Administrative Region (there are no in-person meetings); has been a member of PCOS Challenge (patient support group), Medical/Scientific Advisory Board; Endocrine Society: Member Executive Committee (2015?2018); Secretary-Treasurer (2016?2018); Member Investment Subcommittee (2018?present); and International Advisory Board and Guideline Committee, NHMRC-funded Centre for Research Excellence in PCOS, Melbourne, Australia (June 2016?May 2018); has been a Co-Editor in Chief, Seminars in Reproductive Medicine (2015?2019); Associate Editor, Human Reproduction Update (2017?2020); Associate Editor, Fertility and Sterility (2009?2020); Editorial Editor, Fertility and Sterility (2020?present); Associate Editor, Global Reproductive Health (2017?present); and member, Editorial Board, Endocrinology (2016?2019); is the owner of 1000 shares of Biodesix (BDSX); reports financial or nonfinancial interests as follows: NIH: ZHD1 DSR-K (LR) 1 Loan Repayment Program (Annually, 2008?present), U54 Contraceptive Center Grant, Special Emphasis Panel ZHD1 DSR ? L50 (2017), Special Emphasis Panel/Scientific Review Group 05 CHHD-W 1 Population Sciences Subcommittee (2018), Special Emphasis Panel/Scientific Review Group 10 ZHD1 DSR-M (55): National Centers for Translational Research in Reproduction and Infertility (2020); and Kuwait Foundation for the Advancement of Science (KFAS) (2017) Appalachian Translational Research Network (ATRN) (2018), Karolinska Institute, Stockholm, Sweden (2020). R.A.W. has nothing to disclose. K.R.H. reports grants from the Reproductive Medicine Network (NIH U10HD077680); grants form NIH (NIH R03HD101893 and NIH R01HD100305) outside the submitted work; and consulting fees from AblaCare outside the submitted work. N.S. reports grants from NIH (NIH R25 HD075737). Supported by grants from the National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R25HD075737 [to N.S.], U10 HD39005 [to M.P.D.], U10 HD38992 [to R.S.L.], U10 HD055925 [to H.Z.], and U10 HD077680 [to K.R.H.]). Publisher Copyright: © 2021 American Society for Reproductive Medicine
PY - 2022/2
Y1 - 2022/2
N2 - Objective: To estimate the probability of clinical or multiple pregnancy during ovulation induction (OI)/ovarian stimulation (OS). Design: Secondary analysis of two multicenter randomized clinical trials (combined). Setting: Multicenter. Patients: A total of 750 women with polycystic ovary syndrome and 900 women with unexplained infertility. Interventions: Ovulation induction/OS with either timed intercourse (polycystic ovary syndrome) or intrauterine insemination. Main Outcome Measures: Clinical and multiple pregnancy rates/cycle, cumulative pregnancy rates. Age, body mass index, parity, diagnosis, medication, markers of ovarian reserve, and ovarian response were considered in multivariable regression models for clinical, multiple, and cumulative pregnancy rates. Receiver operating characteristic curves were created for clinical and multiple pregnancy rates. Results: Younger patient and partner age, treatment type, lower body mass index, and medication dose were all associated with clinical pregnancy. Variables associated with multiple pregnancy included the abovementioned variables (except age), in addition to diagnosis, parity, higher antral follicle count, antimüllerian hormone levels, and ovarian response. Gonadotropin use was associated with multiple pregnancy, with progressively increasing odds ratios (cycles 1–4). Receiver operating characteristic curves indicated the model's predictive power to be fair for clinical pregnancy (areas under the curve [95% confidence interval {CI}]: 0.78 [0.75–0.81] for cycle 1 and 0.70 [0.64–0.75] for cycle 4) and good-to-excellent for multiple pregnancy (areas under the curve [95% CI]: 0.78 [0.72–0.84] for cycle 1 and 0.86 [0.78–0.93] for cycle 4). Partner age, lower medication dose, parity, antimüllerian hormone levels, and diagnosis were associated with cumulative pregnancy rates. Conclusions: Using the majority of the factors known to predict the outcome of OI/OS cycles, we constructed an easy-to-use formula that may predict individualized chances of clinical and multiple pregnancy for commonly used fertility treatments (https://pregnancyprediction.medicine.yale.edu/CalDirect.html). Clinical Trial Registration Numbers: Assessing Multiple Intrauterine Gestations after Ovulation Stimulation NCT 1044862; PPCOSII NCT00719186.
AB - Objective: To estimate the probability of clinical or multiple pregnancy during ovulation induction (OI)/ovarian stimulation (OS). Design: Secondary analysis of two multicenter randomized clinical trials (combined). Setting: Multicenter. Patients: A total of 750 women with polycystic ovary syndrome and 900 women with unexplained infertility. Interventions: Ovulation induction/OS with either timed intercourse (polycystic ovary syndrome) or intrauterine insemination. Main Outcome Measures: Clinical and multiple pregnancy rates/cycle, cumulative pregnancy rates. Age, body mass index, parity, diagnosis, medication, markers of ovarian reserve, and ovarian response were considered in multivariable regression models for clinical, multiple, and cumulative pregnancy rates. Receiver operating characteristic curves were created for clinical and multiple pregnancy rates. Results: Younger patient and partner age, treatment type, lower body mass index, and medication dose were all associated with clinical pregnancy. Variables associated with multiple pregnancy included the abovementioned variables (except age), in addition to diagnosis, parity, higher antral follicle count, antimüllerian hormone levels, and ovarian response. Gonadotropin use was associated with multiple pregnancy, with progressively increasing odds ratios (cycles 1–4). Receiver operating characteristic curves indicated the model's predictive power to be fair for clinical pregnancy (areas under the curve [95% confidence interval {CI}]: 0.78 [0.75–0.81] for cycle 1 and 0.70 [0.64–0.75] for cycle 4) and good-to-excellent for multiple pregnancy (areas under the curve [95% CI]: 0.78 [0.72–0.84] for cycle 1 and 0.86 [0.78–0.93] for cycle 4). Partner age, lower medication dose, parity, antimüllerian hormone levels, and diagnosis were associated with cumulative pregnancy rates. Conclusions: Using the majority of the factors known to predict the outcome of OI/OS cycles, we constructed an easy-to-use formula that may predict individualized chances of clinical and multiple pregnancy for commonly used fertility treatments (https://pregnancyprediction.medicine.yale.edu/CalDirect.html). Clinical Trial Registration Numbers: Assessing Multiple Intrauterine Gestations after Ovulation Stimulation NCT 1044862; PPCOSII NCT00719186.
KW - Ovulation induction
KW - individualized prediction models
KW - ovarian stimulation
KW - probability of clinical pregnancy
KW - probability of multiple pregnancy
UR - http://www.scopus.com/inward/record.url?scp=85123949192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123949192&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2021.10.024
DO - 10.1016/j.fertnstert.2021.10.024
M3 - Article
C2 - 35125179
AN - SCOPUS:85123949192
SN - 0015-0282
VL - 117
SP - 408
EP - 418
JO - Fertility and Sterility
JF - Fertility and Sterility
IS - 2
ER -